The CASCADE Project
NCT06117592 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 1400
Last updated 2024-02-21
Summary
People with cancer, treated for cancer, or have been recently treated for cancer are at a higher risk of becoming rapidly unwell. This is referred to as an oncological emergency and can be life-threatening.
The investigators want to see if a new, standardised assessment of acute oncology knowledge and skills of all health care staff (The Acute Oncology Passport) following education and training, has an effect on the diagnosis and treatment of two relatively-common oncological emergencies: sepsis and MSCC? Sepsis is blood poisoning, which causes serious injuries if it is not diagnosed and treated as an emergency and may result in death if not treated quickly enough. MSCC is metastatic spinal cord compression, where the cancer presses on the spinal cord and can cause permanent paralysis. The investigators have chosen these two conditions, not only because of how serious and relatively common they are for people living with cancer, but also because all NHS Trusts in the UK routinely collect and report standardised data about patients who are admitted with suspected sepsis or MSCC.
The investigators plan to compare data that is routinely collected about the diagnosis and treatment of patients with suspected sepsis and MSCC before and after education, training and assessment of staff about acute oncology. The investigators will conduct 'secondary analysis' on the data, as it was originally collected for another purpose. The routinely data collected at five hospital Trusts across the UK from 1st April 2023 to 30th June 2023 and 1st October to 31st December 2023 will be included in this study.
This research is part of a larger UK-wide project, funded until March 2024 by NHS England Workforce, Training and Education Directorate. If acute oncology education, training and assessment of staff is shown to make a difference to patient diagnosis and treatment, the Acute Oncology Passports will be rolled-out nationally.
Conditions
Interventions
- OTHER
-
Education, training and assessment intervention
Staff competence assessment documents for acute oncology knowledge and skills
Sponsors & Collaborators
-
The Christie NHS Foundation Trust
lead OTHER
Principal Investigators
-
Clare Griffin, PhD · The Christie NHS Foundation Trust
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-03-01
- Primary Completion
- 2024-03-29
- Completion
- 2024-03-29
More Related Trials
-
A Study Evaluating Chemotherapy With Fractionated Cisplatin/Gemcitabine Versus Carboplatin/Gemcitabine in the Treatment of Advanced or Metastatic Urothelial Cancer With Impaired Renal Function.
NCT02240017 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas
NCT02192541 ·Status: TERMINATED ·Phase: PHASE1
-
S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer
NCT01498289 ·Status: COMPLETED ·Phase: PHASE2
-
Neoadjuvant Chemotherapy in High - Risk Upper Tract Urothelial Carcinoma
NCT06927128 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor Malignancies
NCT00215501 ·Status: COMPLETED ·Phase: PHASE1
-
7-hydroxystaurosporine and Cisplatin in Treating Patients With Advanced Malignant Solid Tumors
NCT00012194 ·Status: TERMINATED ·Phase: PHASE1
-
UCN-01 and Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors
NCT00006464 ·Status: COMPLETED ·Phase: PHASE1
-
Weekly Paclitaxel and Cyclophosphamide in Metronomic Administration : Dose Escalation Study of Weekly Paclitaxel
NCT01374620 ·Status: COMPLETED ·Phase: PHASE1
-
S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract
NCT00022633 ·Status: TERMINATED ·Phase: PHASE2
-
Taxotere, Cisplatin, and CPT-11 in Advanced Solid Tumor Malignancies
NCT00251407 ·Status: COMPLETED ·Phase: PHASE1
-
Study Of Advanced Gastrointestinal Malignancies And Other Solid Tumors
NCT00660426 ·Status: COMPLETED ·Phase: PHASE1
-
PD-0332991, 5-FU, and Oxaliplatin for Advanced Solid Tumor Malignancies
NCT01522989 ·Status: UNKNOWN ·Phase: PHASE1
-
Phase II (Treatment) Study of Oxaliplatin and Capecitabine in Advanced Head and Neck Malignancies
NCT00266279 ·Status: COMPLETED ·Phase: PHASE2
-
A Non Interventional Study With Paclitaxel Onkovis (Paclitaxel) Utilized for the Treatment of Cancer
NCT01668108 ·Status: COMPLETED
-
Carboplatin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Breast Cancer
NCT00470249 ·Status: TERMINATED ·Phase: PHASE2
-
Cisplatin and Gemcitabine Plus Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00016367 ·Status: COMPLETED ·Phase: PHASE2
-
The Seven Trial: Exploiting the Unfolded Protein Response
NCT06076837 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Carboplatin and Gemcitabine in Treating Patients With Advanced Solid Tumors
NCT00021346 ·Status: COMPLETED ·Phase: PHASE1
-
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
NCT00004913 ·Status: COMPLETED ·Phase: PHASE1
-
Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder Cancer
NCT00487786 ·Status: COMPLETED ·Phase: PHASE1
-
Combination Chemotherapy In Treating Patients With Metastatic or Unresectable Solid Tumors
NCT00005068 ·Status: COMPLETED ·Phase: PHASE1
-
Combination Chemotherapy Following Surgery in Treating Patients With Advanced Bladder Cancer
NCT00003133 ·Status: COMPLETED ·Phase: PHASE1
-
Oxaliplatin Plus Capecitabine in Treating Patients With Metastatic or Recurrent Solid Tumor
NCT00005839 ·Status: COMPLETED ·Phase: PHASE1
-
Combination Chemotherapy in Treating Patients With Metastatic Cancer of an Unknown Site of Origin
NCT00022178 ·Status: UNKNOWN ·Phase: PHASE3
-
Phase II Study of Oxaliplatine-Paclitaxel in Patients With Metastatic Germ Cell Tumor Refractory to Cisplatin
NCT00611962 ·Status: COMPLETED ·Phase: PHASE2